MARKET WIREYahoo Finance • 7h ago
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?Yahoo Finance report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
Why BSX Stock slipped -1.66% Today — RQD Quant Desk Flash
$41.98 -1.66% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $41.77
Boston Scientific Corporation (BSX) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $61.87B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BSX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BSX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Boston Scientific Corporation (NYSE: BSX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $41.98 (-1.66% 1D, market cap $61.87B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, BSX ranks #155 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BSX compare to BDX and MDLN in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), BSX carries a Roarable C (62/100 RQD), trailing P/E of 22.0x, gross margin of 69.0%, and ROIC of 9.2%. By comparison, BDX (Becton Dickinson and Company) holds a C+ grade (67/100 RQD, P/E 32.2x, ROIC 4.9%, cap $54.03B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BSX?
▼
Per BSX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885725), Boston Scientific Corporation generated $20.07B in revenue (+19.9% YoY), $0 in net income, and $3.66B in free cash flow against $43.67B in total assets and $10.22B in total debt. Key quantitative strengths: Strong cash generator (69% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $41.77 (-0.49%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 18.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BSX)Realized 20D OHLCV Swing Band: ±6.2%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY BSX SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+15/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 18.2% FCF Margin ($3.66B FCF) & 69% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B$43.31+5.2% Next Q
70
Q2 (-2Q)Grade B-$45.58-1.1% Next Q
67
Q3 (-1Q)Grade C+$45.06-6.8% Next Q
65
CurrentGrade C$41.98+0.7% Hist 90D α
62
Trajectory: B (70) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the BSX Bull Thesis Could Fail
Even with a 62/100 (C) score, BSX faces multiple-compression risk if 22.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 66.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($44.51) or 200D SMA ($56.05) invalidates the momentum regime and cuts Target Base ($42.74) toward Bear Floor ($33.34).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BSX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BSX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BSX Stock slipped -1.66% Today — RQD Quant Desk Flash
Boston Scientific Corporation (BSX) slipped -1.66% to $41.98, trading at 4% of its 52-week range ($39.57 – $105.65). Solid 69% profit margin (9% return on capital), mixed timing at 22x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 4% of its 52-week range ($39.57 – $105.65) with RSI-14 at 43 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.2% around $41.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 69% gross margin and $3.7B annual free cash flow.
Live BSX Headlines & Catalysts
MARKET WIREMoomoo • 10h ago
Why Boston Scientific (BSX) Stock Is Down TodayMoomoo report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 13h ago
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 16h ago
Boston Scientific: A Better Valuation, But The Turnaround Needs Proof (NYSE:BSX)Seeking Alpha report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHTradingView • 19h ago
Boston Scientific Corporation Stock 12‑Month Price Target Cut to $57.29, Implies 27% UpsideTradingView report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 22h ago
Why Boston Scientific (BSX) Outpaced the Stock Market TodayYahoo Finance report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSeeking Alpha • 1d ago
Boston Scientific stock drops on duidance cut (BSX:NYSE)Seeking Alpha report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock DownTradingView report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3h ago
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpointsBoston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. T
MARKET WIREFintel • 10h ago
Boston Scientific Consensus Price Target Lowered by 10.06% to $57.12ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (BSX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BSX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.16%▼ DESCENDING CHANNEL
2026-11-02O $42.43H $42.69L $41.98C $41.98VOL 31.76M
RES: $45.18SUP: $39.44SMA50: $44.51SMA200: $56.05
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BSX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
15.7%/yr Implied 5Y Growth
vs. +19.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BSX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BSX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BSX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BSX)
Health Care Rank #155 of 1016
⚔️ BDX vs BSX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BSX vs. BDX, MDLN, MMM, RMD)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Boston Scientific Corporation (BSX) ranks #155 by composite RQD confidence (62/100, grade C) and #33 by equity capitalization ($61.87B). Within this direct 5-issuer industry benchmark cohort, BSX leads on earnings valuation at 22.0x trailing P/E, while MMM leads on capital efficiency and profitability with 32.9% ROIC and 39.9% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with BSX at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BSX
ACTIVE
Boston Scientific Corporation | C | 62/100 | 22.0x | 69.0% | 9.2% | -1.66% | $61.87B | Benchmark Subject |
| BDX Becton Dickinson and Company | C+ | 67/100 | 32.2x | 45.4% | 4.9% | -0.23% | $54.03B | /bdx-vs-bsx → |
| MDLN Medline Inc. | D | 44/100 | — | — | 8.2% | +0.38% | $42.07B | /mdln-vs-bsx → |
| MMM 3M Company | C | 65/100 | 28.2x | 39.9% | 32.9% | -1.70% | $91.65B | /mmm-vs-bsx → |
| RMD ResMed Inc. | A | 86/100 | 25.4x | 59.4% | 22.9% | -9.05% | $35.56B | /rmd-vs-bsx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000885725In its most recent audited fiscal period (FY2025, filed 2025-12-31), Boston Scientific Corporation (BSX) reported GAAP revenue of $20.07B (+19.9% vs. FY2024 revenue of $16.75B , and +41.0% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $4.53B, and free cash flow of $3.66B (+38.3% YoY). On the balance sheet, BSX closed FY2025 with $43.67B in total assets against $10.22B in total debt (Altman Z-Score: 2.77, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $20.07B | $0 | $4.53B | $3.66B | $43.67B | $10.22B |
| FY2024 (FY) | 2024-12-31 | $16.75B | $0 | $3.44B | $2.65B | $39.40B | $9.22B |
| FY2023 (FY) | 2023-12-31 | $14.24B | $0 | $2.50B | $1.86B | $34.03B | $7.96B |
3. BSX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BSX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Boston Scientific Corporation (NYSE: BSX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $41.98 (-1.66% 1D, market cap $61.87B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, BSX ranks #155 in composite RQD confidence.
How does BSX compare to BDX and MDLN in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), BSX carries a Roarable C (62/100 RQD), trailing P/E of 22.0x, gross margin of 69.0%, and ROIC of 9.2%. By comparison, BDX (Becton Dickinson and Company) holds a C+ grade (67/100 RQD, P/E 32.2x, ROIC 4.9%, cap $54.03B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BSX?
Per BSX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885725), Boston Scientific Corporation generated $20.07B in revenue (+19.9% YoY), $0 in net income, and $3.66B in free cash flow against $43.67B in total assets and $10.22B in total debt. Key quantitative strengths: Strong cash generator (69% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BSX trading relative to its 50-day, 200-day, and 52-week technical levels?
BSX last traded at $41.98 (-1.66% on volume of 22,467,159 shares), positioning the stock -5.68% below its 50-day simple moving average ($44.51) and -25.10% below its 200-day simple moving average ($56.05). Across its 52-week range of $39.57 to $105.65, BSX sits at the 3.6% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($39.38 to $44.58).
BSX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BSX stock moving today?
Why BSX Stock slipped -1.66% Today — RQD Quant Desk Flash. Solid 69% profit margin (9% return on capital), mixed timing at 22x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 62/100 (C)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BSX — Boston Scientific Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:10:45Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BSX scores 62 out of 100, graded C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:
- Fundamental Cash Engine: 15 / 20. Per the RQD rating, this pillar reflects ROIC of 9.2% and an FCF yield of 5.91%. For a prospective investor, this indicates moderate cash generation relative to the capital employed, with a valuation tradeoff: the FCF yield provides some support for the price but does not signal an exceptionally cheap entry.
- Whale / 13F Flow: 7 / 20. Per the RQD rating, this is the weakest pillar, covering institutional accumulation and options positioning. The source data does not include 13F holder detail, so the low score signals limited institutional conviction as measured by this model, which is a caution for a prospective investor.
- Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. Insider and congressional activity is moderate in the model's assessment; the underlying trade detail is not in the source data.
- Macro Regime Fit: 11 / 20. Per the RQD rating, beta is 0.99, meaning the model views BSX as roughly market-correlated in volatility, with sector sensitivity weighing on the score. An investor should expect the stock to track broad market moves rather than diverge meaningfully.
- Forensic Balance Sheet: 14 / 20. Per the RQD rating, Altman Z is 2.77, Piotroski F is 8/9, and Debt/Equity is 0.36. These metrics point to a relatively sound balance sheet, a meaningful upside driver for a prospective investor focused on financial resilience.
Overall, the composite of 62 reflects a mix of solid balance-sheet strength and cash generation offset by weak institutional flow and market-sensitivity considerations. Upside drivers include the forensic and cash pillars; the principal valuation tradeoff is that P/E (TTM) of 22 sits above forward P/E of 18.5, implying expected earnings improvement that the source data does not independently confirm.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $20074.0M | $3613.0M | $0.0M | N/A | $3658.0M | $1965.0M | $10219.5M |
| FY 2024 | $16747.0M | $2603.0M | $0.0M | N/A | $2645.0M | $414.0M | $9218.4M |
| FY 2023 | $14240.0M | $2343.0M | $0.0M | N/A | $1862.2M | N/A | $7962.4M |
Revenue grew from $14240.0M (FY 2023) to $20074.0M (FY 2025) per the SEC financials, and operating income rose over the same span. Reported net income is $0.0M in each period and EPS is N/A, so profitability conclusions rely on the market-data margins rather than the filed net income line. Per the Roarable RQD rating, ROIC is 9.2%, the Altman Z-Score is 2.77, the Piotroski F-Score is 8/9, and Debt/Equity is 0.36, indicating a balance sheet the model rates as sound. Reported debt rose from $7962.4M to $10219.5M while cash moved from N/A to $1965.0M.
Open Questions
- What specific operational, product, or regulatory events drove the 52-week decline from $105.65 to $39.57, and which of them are resolved?
- What is the source of the gap between reported net income of $0.0M and the 14% net margin cited in market data?
- What is the institutional and insider holder composition behind the 7/20 whale-flow pillar score?
- Do the Stryker comparison and "turnaround" framing reflect company-specific guidance that the source data does not capture?
- What drove the rise in debt from $7962.4M (FY 2023) to $10219.5M (FY 2025), and how is it being serviced against the $1965.0M cash position?
BSX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Boston Scientific Corporation (BSX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 7h ago
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy? Yahoo Finance report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 10h ago
Why Boston Scientific (BSX) Stock Is Down Today Moomoo report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 13h ago
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 16h ago
Boston Scientific: A Better Valuation, But The Turnaround Needs Proof (NYSE:BSX) Seeking Alpha report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH TradingView • 19h ago
Boston Scientific Corporation Stock 12‑Month Price Target Cut to $57.29, Implies 27% Upside TradingView report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 22h ago
Why Boston Scientific (BSX) Outpaced the Stock Market Today Yahoo Finance report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 1d ago
Boston Scientific stock drops on duidance cut (BSX:NYSE) Seeking Alpha report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down TradingView report covering Boston Scientific Corporation (BSX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BSX Bull vs. Bear Conversation Board — What's Your Call at $41.98?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BSX 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $46.11 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BSX (C • RQD 62/100) a Buy at $42.69?
Welcome to the BSX (Boston Scientific Corporation) Roar Pit. Current RQD Composite is 62/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $32.44 (-24.0%)
Spot @ $42.69 Pump the brakes on BSX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BSX, but look at what you are paying: 22.0x trailing P/E with 69.0% gross margins. Unless Boston Scientific Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $54.22 (+27.0%)
Spot @ $42.69 BSX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BSX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $42.69 (52-wk range $39.57 - $105.65), any beat on forward guidance forces shorts and underweight funds to chase.